Verici Dx highlights patient perspective in transplant care

Verici Dx Plc

Verici Dx is using its latest Coffee and Cases session to directly connect its transplant diagnostics offering with real-world patient outcomes, highlighting factors that influence clinical adoption beyond technical performance.

The event, scheduled for 26 March 2026 at 12pm CST, features Tiffany Archibald, a patient advocate and rare disease specialist who has undergone three kidney transplants. Her experience provides a practical lens on the challenges faced across the transplant journey, including diagnosis, monitoring, and long-term care.

Adoption in transplant diagnostics depends on how effectively tools fit into clinical workflows and patient management. By focusing on lived experience, Verici Dx is reinforcing the role its technology can play in addressing gaps in care, particularly in complex or underdiagnosed conditions.

Verici Dx Coffee Cases (VRCI)

Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Search